Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Inventiva S.A. (IVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva Reports Preliminary 2023 First-Half Financial Information 1 and Business update Daix , Long Island City , July 27, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update. Preliminary Financial Results As of June 30, 2023, the Company’s cash and cash equivalents amounted to €31.2 million, short-term deposits to 0.05 million 2 , and long-term deposit to €9.3 million 3 , compared to €86.7 million, €1.0 million a..."
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023"
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China"
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva reports 2023 First Quarter Financial Information 1 and provides a corporate update Daix , Long Island City , May 16, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today reported financial information for the first quarter of 2023, including its cash, cash equivalents and revenues, and provided a corporate update. Financial Results"
05/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice of meeting",
"Notice of meeting"
05/04/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
04/17/2023 6-K Quarterly results
03/29/2023 6-K Quarterly results
02/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva reports preliminary financial results for Full-Year 2022 1 Daix , Long Island City , February 14, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Results 1 Cash and cash equivalents, short-term deposits, R&D Expenses, Net cash used in operating activities, Net cash generated from investing activities and Net cash generated from financing activities. As of December 31, 2022, the Company had €86.7 million of cash and cash equivalents and €1.0 million of sho..."
01/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023 Daix , Long Island City , January 26, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ General Meeting. The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon , under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the ..."
01/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Second notice of meeting to the Ordinary and Extraordinary General Meeting",
"Second notice of meeting to the Ordinary and Extraordinary General Meeting"
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis"
01/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Proxy Card",
"Voting Instructions",
"Preparatory Documents Announcement",
"Statement of Voting Rights"
12/19/2022 6-K Quarterly results
12/12/2022 6-K Quarterly results
11/21/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
10/31/2022 6-K Quarterly results
09/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO ITEM 601 OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT"
09/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China",
"Interim Financial Report",
"Inventiva reports its 2022 first-half financial results and provides a corporate update ► Cash position 1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 ► Receipt of a €4 million milestone payment from Inventiva’ s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flow ► Inventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank 2 ► Inventiva raised approximately €14.7 million through a combination of Inventiva’ s At-The-Market program and new state-backed bank financing ► Screening of the first patients in Phase IIa combination trial LEGEN..."
07/28/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
05/20/2022 6-K Quarterly results
05/19/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/02/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Combined General Meeting of May 19, 2022 Availability of the preparatory documents Daix , Long Island City , April 28, 2022 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 19, 2022. Shareholders are invited to participate in the annual Combined General Meeting that will be held on May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon . The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined Genera...",
"Statement of total voting rights and shares forming the company’ s share capital as of April 11, 2022"
04/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Proxy Card",
"Voting Instructions"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy